Skip to content

Familial Cancer Registry and DNA Bank

Familial Cancer Registry and DNA Bank

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02083224
Enrollment
2000
Registered
2014-03-11
Start date
2000-01-31
Completion date
Unknown
Last updated
2014-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

Clinical cancer genetics is an emerging new field in medical oncology, and has been incorporated into routine oncology practice in many leading medical institutions in North America and Europe. Cancer genetics is the study of genetic factors contributing to carcinogenesis. In the last 5-10 years, genes responsible for various well-defined hereditary cancer syndromes have been cloned. These include the BRCAJ/2 genes in hereditary breast and ovarian cancer syndrome, the A4PC gene in Familial Adenomatous Polyposis, and the mismatch repair genes (hMLH1, hMSH2, hPMS1, hPMS2, hMSH6) in hereditary non-polyposis colorectal cancer (HNPCC). One of the goals of a clinical cancer genetics service is to identify families at risk for hereditary cancer syndromes, provide genetic counseling, and offer genetic testing when appropriate. The identification of causative genes in hereditary cancer syndromes together with the advent of genetic testing is starting to have an impact on clinical management. The ability to identify a gene mutation in a cancer family allows predictive testing, stratifying at-risk family members into carriers who will benefit from aggressive surveillance and/or preventive options, and non-carriers who may be spared unnecessary surveillance. Appropriate use of genetic testing will ultimately result in medical cost reduction. The investigators hypothesize that the clinical characteristics and genetic factors contributing to hereditary cancer in the Singaporean Asian population are distinct from those described for Western patients.

Interventions

None listed

Sponsors

National University Hospital, Singapore
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any individual with very early onset cancer (eg diagnosed before age 40). * Any family with three or more first- or second-degree relatives with the same cancer * Any individual with two or more different primary cancers * Any family that fulfils diagnostic criteria for known hereditary cancer syndromes

Exclusion criteria

Nil

Design outcomes

Primary

MeasureTime frame
Change in genetics testing method2 years

Countries

Singapore

Contacts

Primary ContactSoo Chin Lee, MBBS, MRCP
Soo_Chin_Lee@nuhs.edu.sg+65 6779 5555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026